Cancer

IONETIX Produces First Batch of Actinium-225

LANSING, Mich., June 7, 2024 /PRNewswire/ -- IONETIX, a leading cyclotron technology innovator, isotope producer, and radiopharmaceutical manufacturer, announced today…

7 months ago

Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation

DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

7 months ago

Kanazawa University research: Sensing a biomarker

KANAZAWA, Japan, June 7, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Biosensors and Bioelectronics: X…

7 months ago

AI Based Wound Care Software Market to Record an Exponential CAGR by 2031 – Exclusive Report by InsightAce Analytic

JERSEY CITY, N.J., June 6, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report…

7 months ago

Buck Institute and Sens.ai Collaborate to Study Brain Aging

New Longevity Tech Collaboration Will Research and Develop First-Ever Biological Clock for the Brain WHISTLER, BC, June 6, 2024 /PRNewswire/…

7 months ago

Northern Arizona Healthcare Selects Noetic Consultants as Brand Partner

Comprehensive brand and reputation analysis will center around listening FLAGSTAFF, Ariz., June 6, 2024 /PRNewswire/ -- Northern Arizona Healthcare (NAH),…

7 months ago

Health Catalyst Acquires Oncology-Focused Health Technology Company Carevive

SALT LAKE CITY, June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and…

7 months ago

How Merck Scientists Are Driving Next-Generation Cancer Research

The company's scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit…

7 months ago

Theralase(R) Successfully Destroys Lung Cancer

TORONTO, ON / ACCESSWIRE / June 6, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical…

7 months ago

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing…

7 months ago